title: SCORE Study report 3: study design and baseline characteristics.
abstract: OBJECTIVE
  To describe the baseline characteristics of the participants in the Standard Care versus COrticosteroid for REtinal Vein Occlusion (SCORE) Study and to compare with cohorts from other retinal vein occlusion trials. The design of the SCORE Study is also described.
  
  
  METHODS
  Two, multicenter, Phase III, randomized clinical trials, one involving participants with central retinal vein occlusion (CRVO) and one involving participants with branch retinal vein occlusion (BRVO).
  
  
  METHODS
  A total of 682 participants, including 271 with CRVO and 411 with BRVO.
  
  
  METHODS
  Demographic and study eye characteristics are summarized and compared between the CRVO and BRVO study participants.
  
  
  METHODS
  Baseline ophthalmic characteristics, including visual acuity and duration of macular edema before enrollment, and medical history characteristics, including diabetes mellitus and hypertension.
  
  
  RESULTS
  In the CRVO trial, at baseline, mean visual acuity letter score was 51 ( approximately 20/100), mean optical coherence tomography (OCT)-measured central subfield thickness was 595 microns, mean area of retinal thickening in the macular grid on color photography was 12.3 disc areas (DA), and mean area of fluorescein leakage was 11.0 DA. In the BRVO trial, at baseline, mean visual acuity letter score was 57 ( approximately 20/80), mean OCT-measured central subfield thickness was 491 microns, mean area of retinal thickening in the macular grid on color photography was 7.5 DA, and the mean area of fluorescein leakage was 6.1 DA.
  
  
  CONCLUSIONS
  Differences observed in baseline visual acuity, OCT-measured retinal thickness, area of retinal thickening on color photography, and area of fluorescein leakage support the evaluation of CRVO and BRVO in separate trials.
  
  
  BACKGROUND
  The authors have no proprietary or commercial interest in any of the materials discussed in this article.
authors.affiliation: University of Wisconsin Fundus Photograph Reading Center, Madison, WI, USA.
authors.forename: Michael S
authors.initials: MS
authors.lastname: Ip
authors.forename: Neal L
authors.initials: NL
authors.lastname: Oden
authors.forename: Ingrid U
authors.initials: IU
authors.lastname: Scott
authors.forename: Paul C
authors.initials: PC
authors.lastname: VanVeldhuisen
authors.forename: Barbara A
authors.initials: BA
authors.lastname: Blodi
authors.forename: Maria
authors.initials: M
authors.lastname: Figueroa
authors.forename: Andrew
authors.initials: A
authors.lastname: Antoszyk
authors.forename: Michael
authors.initials: M
authors.lastname: Elman
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007267:Injections; D017075:Laser Coagulation; D008269:Macular Edema / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012107:Research Design; D012160:Retina / Q000473:pathology; D012170:Retinal Vein Occlusion / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D019233:Retreatment; D041623:Tomography, Optical Coherence; D014222:Triamcinolone Acetonide / Q000008:administration & dosage* / Q000009:adverse effects; D014792:Visual Acuity / Q000502:physiology; D014822:Vitreous Body
chemical_list: D005938:Glucocorticoids; D014222:Triamcinolone Acetonide